Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 21: Laboratory monitoring of which of the following is desirable with low molecular weight heparin therapy?

A. aPTT
B. CT
C. PT
D. Anti-factor Xa activity (Correct Answer)

Explanation: **Explanation:** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin and Dalteparin, act primarily by inhibiting **Factor Xa** rather than Thrombin (Factor IIa). This is due to their smaller saccharide chain length, which is insufficient to bridge Antithrombin to Thrombin but effective for Factor Xa inhibition. **1. Why Anti-factor Xa activity is correct:** LMWHs have a predictable pharmacokinetic profile and do not significantly prolong the aPTT at therapeutic doses. Therefore, routine monitoring is **not** required for most patients. However, in specific populations where clearance is unpredictable—such as **pregnant women, morbidly obese patients, or those with renal insufficiency**—monitoring **Anti-factor Xa levels** is the gold standard to ensure safety and efficacy. **2. Why other options are incorrect:** * **aPTT (Activated Partial Thromboplastin Time):** This is the standard monitoring tool for **Unfractionated Heparin (UFH)**. LMWH has a much higher ratio of Anti-Xa to Anti-IIa activity (3:1 or 4:1), making aPTT an insensitive and unreliable measure. * **PT (Prothrombin Time):** This measures the extrinsic pathway and is used to monitor **Warfarin** therapy (INR). * **CT (Clotting Time):** This is an obsolete, non-specific bedside test rarely used in modern clinical practice for heparin monitoring. **Clinical Pearls for NEET-PG:** * **Antidote:** Protamine sulfate completely reverses UFH but only **partially reverses** LMWH (approx. 60-75%). * **Renal Clearance:** LMWH is primarily excreted by the kidneys; thus, it is contraindicated in severe renal failure (CrCl <30 ml/min), where UFH is preferred. * **HIT Risk:** The risk of Heparin-Induced Thrombocytopenia (HIT) is significantly lower with LMWH compared to UFH.

Question 22: Acute severe bleeding as a result of Warfarin therapy can be controlled by all EXCEPT?

A. Withhold the anticoagulant
B. Vitamin K1
C. Heparin (Correct Answer)
D. Fresh frozen plasma

Explanation: **Explanation:** The goal of managing warfarin-induced bleeding is to rapidly restore functional clotting factors (II, VII, IX, and X). **Why Heparin is the correct answer (The "EXCEPT"):** Heparin is an **anticoagulant**, not a procoagulant. It works by activating Antithrombin III, which inhibits Thrombin and Factor Xa. Administering Heparin to a patient already bleeding from Warfarin toxicity would **exacerbate the hemorrhage** and worsen the clinical outcome. Therefore, it has no role in controlling acute bleeding. **Why the other options are wrong (Management of Warfarin Toxicity):** * **Withhold the anticoagulant (Option A):** This is the first step in managing any drug toxicity. In cases of minor elevation of INR without bleeding, simply skipping doses may suffice. * **Vitamin K1 (Phytonadione) (Option B):** This is the specific physiological antagonist for Warfarin. It promotes the hepatic synthesis of clotting factors. However, it takes 6–24 hours to work as it requires new protein synthesis. * **Fresh Frozen Plasma (FFP) (Option D):** In **acute severe bleeding**, FFP is used because it contains pre-formed clotting factors, providing immediate replacement while waiting for Vitamin K to take effect. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice for Immediate Reversal:** **Prothrombin Complex Concentrate (PCC)** is preferred over FFP for rapid reversal as it works faster and carries less risk of volume overload. 2. **Monitoring:** Warfarin is monitored by **PT/INR** (Extrinsic pathway), while Heparin is monitored by **aPTT** (Intrinsic pathway). 3. **Teratogenicity:** Warfarin is contraindicated in pregnancy (causes Fetal Warfarin Syndrome); Heparin is the anticoagulant of choice for pregnant women. 4. **Warfarin-Induced Skin Necrosis:** Caused by a rapid drop in Protein C levels; managed by stopping Warfarin and administering Vitamin K and Heparin.

Question 23: All are true about warfarin except:

A. Acts through inhibition of coagulation factor IX
B. Protamine sulfate reverses its action (Correct Answer)
C. Monitoring is done through INR
D. Target INR with warfarin is generally 2-3

Explanation: **Explanation:** Warfarin is an oral anticoagulant that acts as a **Vitamin K epoxide reductase (VKOR)** inhibitor. It interferes with the gamma-carboxylation of Vitamin K-dependent clotting factors **II, VII, IX, and X**, as well as proteins C and S. **Why Option B is the correct "Except" answer:** **Protamine sulfate** is the specific antidote used to reverse the effects of **Heparin**, not Warfarin. Protamine is a strongly basic protein that neutralizes acidic heparin molecules. To reverse Warfarin, the treatment of choice is **Vitamin K** (slow onset) or **Prothrombin Complex Concentrate (PCC)/Fresh Frozen Plasma (FFP)** for immediate reversal in cases of life-threatening bleeding. **Analysis of other options:** * **Option A:** Warfarin inhibits the synthesis of functional factor IX (along with II, VII, and X). * **Option C:** Warfarin therapy is monitored using the **Prothrombin Time (PT)**, which is standardized globally as the **International Normalized Ratio (INR)**. * **Option D:** For most clinical indications (like Atrial Fibrillation or DVT), the therapeutic target INR is **2.0–3.0**. For mechanical prosthetic heart valves, a higher range (2.5–3.5) may be required. **High-Yield Clinical Pearls for NEET-PG:** * **Warfarin-induced Skin Necrosis:** Occurs due to a rapid decline in Protein C (short half-life), leading to a transient hypercoagulable state. This is why "Heparin bridging" is necessary. * **Teratogenicity:** Warfarin is contraindicated in pregnancy (Category X) as it causes **Fetal Warfarin Syndrome** (stippled epiphyses, nasal hypoplasia). * **Metabolism:** It is metabolized by **CYP2C9**; enzyme inhibitors (e.g., Amiodarone) increase bleeding risk, while inducers (e.g., Rifampin) decrease its efficacy.

Question 24: A patient with Renal cell carcinoma is on treatment with Erythropoetin. Erythropoetin use may be associated with all of the following, except:

A. Decreased reticulocytes (Correct Answer)
B. Increased hematocrit
C. Increased hemoglobin
D. Eliminates need for transfusion

Explanation: ### Explanation **Correct Option: A (Decreased reticulocytes)** **Mechanism and Reasoning:** Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the peritubular interstitial cells of the kidney [1]. It acts on the bone marrow to stimulate the proliferation and differentiation of erythroid progenitor cells (CFU-E) [1]. The earliest measurable response to EPO therapy is an **increase in the reticulocyte count** (immature red blood cells), which typically occurs within 7–10 days [2]. Therefore, saying EPO causes *decreased* reticulocytes is physiologically incorrect, making it the right answer for an "except" question. **Analysis of Incorrect Options:** * **B & C (Increased hematocrit and hemoglobin):** These are the primary therapeutic goals of EPO [2]. As reticulocytes mature into erythrocytes, the total red cell mass increases, leading to a rise in hemoglobin levels and hematocrit [2]. * **D (Eliminates need for transfusion):** In patients with chronic anemia (e.g., due to Chronic Kidney Disease or chemotherapy), EPO is used specifically to maintain hemoglobin at a target level (usually 10–12 g/dL), thereby reducing or eliminating the requirement for frequent blood transfusions and avoiding iron overload [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Side Effect:** Hypertension (due to rapid increase in peripheral resistance and blood viscosity). * **Black Box Warning:** Increased risk of thromboembolic events (Stroke, MI) if Hemoglobin is targeted >11-12 g/dL [1]. * **Iron Stores:** EPO therapy can lead to "functional iron deficiency" because iron utilization outpaces supply; thus, iron supplementation is often required concurrently [2]. * **Indications:** Anemia of CKD, Anemia in HIV (Zidovudine-induced), and Anemia in cancer patients on chemotherapy [2].

Question 25: A patient diagnosed with deep vein thrombosis is being treated with heparin. Which of the following tests is used to monitor and adjust its dosage?

A. Platelet count
B. Prothrombin time
C. Bleeding time
D. Activated partial thromboplastin time (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Activated partial thromboplastin time (aPTT)** **Why it is correct:** Unfractionated Heparin (UFH) acts by binding to **Antithrombin III**, which subsequently inactivates **Factors IIa (Thrombin) and Xa** (and to a lesser extent IXa, XIa, and XIIa). Since these factors are primarily involved in the **intrinsic and common pathways** of the coagulation cascade, the **aPTT** is the standard test for monitoring. The therapeutic goal is typically to maintain the aPTT at 1.5 to 2.5 times the normal control value. **Why the other options are incorrect:** * **A. Platelet count:** While heparin can cause Heparin-Induced Thrombocytopenia (HIT), platelet counts are used to monitor for this adverse effect, not to adjust the anticoagulant dosage. * **B. Prothrombin time (PT/INR):** PT monitors the **extrinsic pathway** (Factor VII). It is the standard test for monitoring **Warfarin** therapy, not heparin. * **C. Bleeding time:** This test assesses **platelet function** and vascular integrity, rather than the soluble coagulation cascade targeted by heparin. **High-Yield Clinical Pearls for NEET-PG:** * **LMWH Monitoring:** Low Molecular Weight Heparins (e.g., Enoxaparin) have a predictable response and usually do not require monitoring. If needed (e.g., in pregnancy or renal failure), **Factor Xa assay** is used. * **Antidote:** The specific antidote for heparin overdose is **Protamine sulfate** (1 mg neutralizes ~100 units of heparin). * **Mechanism Difference:** UFH inactivates both IIa and Xa (ratio 1:1), whereas LMWH mainly inactivates Xa (ratio 3:1). * **Fondaparinux:** A synthetic pentasaccharide that selectively inhibits Factor Xa only.

Question 26: In contrast to heparin, what is a characteristic difference of enoxaparin?

A. Can be used without monitoring the patient's aPTT (Correct Answer)
B. Is less likely to have a teratogenic effect
C. Is more likely to be given intravenously
D. Is more likely to cause thrombosis and thrombocytopenia

Explanation: **Explanation:** The fundamental difference between Unfractionated Heparin (UFH) and Low Molecular Weight Heparins (LMWH) like **Enoxaparin** lies in their molecular weight and pharmacological predictability. **1. Why Option A is Correct:** Enoxaparin has a smaller molecular chain, which results in a more predictable pharmacokinetic profile and better bioavailability after subcutaneous injection. Unlike UFH, which binds non-specifically to plasma proteins and requires frequent monitoring of **activated Partial Thromboplastin Time (aPTT)**, Enoxaparin has a minimal effect on aPTT. Monitoring is generally unnecessary except in specific populations (e.g., renal failure, pregnancy, or extreme obesity), where **Factor Xa levels** are measured instead. **2. Why the other options are incorrect:** * **Option B:** Neither UFH nor Enoxaparin crosses the placenta; both are considered safe in pregnancy and are **not teratogenic**. * **Option C:** Enoxaparin is primarily administered **subcutaneously**. UFH can be given both intravenously (for rapid anticoagulation) and subcutaneously. * **Option D:** Enoxaparin has a **lower risk** of causing Heparin-Induced Thrombocytopenia (HIT) and thrombosis compared to UFH because it has less affinity for Platelet Factor 4 (PF4). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** UFH inhibits both Thrombin (IIa) and Factor Xa (1:1 ratio). LMWH (Enoxaparin) predominantly inhibits **Factor Xa** (ratio of Xa:IIa is 3:1). * **Antidote:** **Protamine sulfate** completely neutralizes UFH but only partially neutralizes LMWH. * **Elimination:** Enoxaparin is **renally excreted**; therefore, it is contraindicated or requires dose adjustment in patients with a Creatinine Clearance <30 ml/min. UFH is preferred in severe renal failure.

Question 27: Which one of the following statements is FALSE about Ticlopidine?

A. Inhibits platelet function by inducing a thrombasthenia-like state.
B. Stimulates platelet aggregation and clot retraction. (Correct Answer)
C. Prolongs the bleeding time.
D. Directly interacts with platelet membrane glycoprotein IIb/IIIa receptors.

Explanation: ### Explanation **Ticlopidine** is a first-generation **P2Y12 receptor antagonist** (Thienopyridine class). It works by irreversibly inhibiting the binding of Adenosine Diphosphate (ADP) to its receptors on platelets. **1. Why Option B is the Correct (False) Statement:** Ticlopidine is an **antiplatelet drug**. Its primary therapeutic goal is to **inhibit** platelet aggregation and prevent thrombus formation. It does not stimulate aggregation; rather, it prevents the activation of the GP IIb/IIIa complex, which is essential for fibrinogen binding and subsequent clot retraction. Therefore, saying it "stimulates" these processes is physiologically incorrect. **2. Analysis of Other Options:** * **Option A:** By blocking ADP receptors, Ticlopidine prevents the conformational change in the GP IIb/IIIa receptor. This mimics **Glanzmann’s Thrombasthenia** (a genetic deficiency of GP IIb/IIIa), effectively inducing a "thrombasthenia-like state." * **Option C:** Since it inhibits the primary step of platelet plug formation, it significantly **prolongs bleeding time**. * **Option D:** While its primary target is the P2Y12 receptor, the downstream effect is a direct interference with the activation and function of the **GP IIb/IIIa receptor** membrane complex. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Irreversible P2Y12 inhibition (Prodrug). * **Adverse Effects:** The most serious side effect is **Severe Neutropenia/Agranulocytosis** (requires frequent CBC monitoring in the first 3 months). It can also cause **Thrombotic Thrombocytopenic Purpura (TTP)**. * **Current Status:** Largely replaced by **Clopidogrel** (better safety profile) and **Prasugrel/Ticagrelor** (faster onset/more potent). * **Clinical Use:** Prevention of stroke in patients intolerant to Aspirin and prevention of stent thrombosis.

Question 28: What is the mechanism of action of apixaban?

A. Inhibition of factor Xa (Correct Answer)
B. Inhibition of thrombin
C. Stimulation of antithrombin
D. Vitamin K antagonism

Explanation: **Explanation:** **Mechanism of Action (Correct Answer: A)** Apixaban is a **Direct Oral Anticoagulant (DOAC)** that acts as a potent, reversible, and highly selective **direct inhibitor of Factor Xa**. Factor Xa is the pivotal point where the intrinsic and extrinsic coagulation pathways converge to form the "common pathway." By binding directly to the active site of both free and clot-bound Factor Xa, apixaban prevents the conversion of prothrombin (Factor II) to thrombin (Factor IIa), thereby inhibiting fibrin clot formation. **Analysis of Incorrect Options:** * **B. Inhibition of thrombin:** This is the mechanism of **Direct Thrombin Inhibitors (DTIs)** like **Dabigatran** (oral) or Argatroban and Bivalirudin (parenteral). * **C. Stimulation of antithrombin:** This describes the mechanism of **Heparin** and **Low Molecular Weight Heparins (LMWH)**. They act indirectly by accelerating the activity of Antithrombin III, which then inactivates Factor Xa and Thrombin. * **D. Vitamin K antagonism:** This is the mechanism of **Warfarin**. It inhibits the enzyme Vitamin K Epoxide Reductase (VKOR), preventing the γ-carboxylation of Factors II, VII, IX, and X. **High-Yield NEET-PG Pearls:** * **The "Xabans":** Remember that drugs ending in "-xaban" (Apixaban, Rivaroxaban, Edoxaban) target Factor **Xa** (the "Xa" is in the name). * **Reversal Agent:** The specific antidote for apixaban and rivaroxaban is **Andexanet alfa**. * **Clinical Advantage:** Unlike Warfarin, apixaban does not require routine INR monitoring and has fewer drug-food interactions. * **Excretion:** Apixaban has significant fecal excretion, making it a preferred DOAC in patients with mild-to-moderate renal impairment compared to dabigatran.

Question 29: What is the difference between iron sorbitol-citric acid and iron dextran?

A. Iron sorbitol-citric acid cannot be injected intravenously. (Correct Answer)
B. Iron sorbitol-citric acid is not bound to transferrin in plasma.
C. Iron sorbitol-citric acid is not excreted in urine.
D. Iron sorbitol-citric acid produces fewer side effects.

Explanation: ### Explanation The primary difference between **Iron Sorbitol-Citric Acid (Jectofer)** and **Iron Dextran** lies in their molecular weight and route of administration. **1. Why Option A is Correct:** Iron sorbitol-citric acid is a low-molecular-weight complex. Due to its small molecular size, it is rapidly absorbed into the systemic circulation directly from the injection site. If given intravenously, it would saturate transferrin too quickly, leading to high levels of free iron in the blood, which is highly toxic. Therefore, it is strictly administered via **deep intramuscular (IM)** injection using the Z-track technique. In contrast, Iron Dextran is a high-molecular-weight complex that can be given both IM and IV. **2. Analysis of Incorrect Options:** * **Option B:** Both forms eventually bind to transferrin in the plasma to be transported to the bone marrow for erythropoiesis. * **Option C:** Unlike Iron Dextran (which is too large to be filtered), roughly **30% of Iron Sorbitol-Citric Acid is excreted in the urine** because of its small molecular weight. This can cause the urine to turn dark on standing, a benign but notable side effect. * **Option D:** Iron sorbitol-citric acid does not necessarily produce fewer side effects; in fact, it is often associated with more systemic symptoms like a metallic taste, palpitations, and local pain compared to modern IV iron preparations. **3. NEET-PG High-Yield Pearls:** * **Z-track Technique:** Essential for IM iron to prevent skin staining. * **Iron Dextran Warning:** Carries the highest risk of **Type I Hypersensitivity (Anaphylaxis)**; a test dose is mandatory. * **Iron Sucrose/Ferric Carboxymaltose:** Preferred modern IV agents as they do not require a test dose and have lower anaphylaxis risk. * **Contraindication:** Never give oral and parenteral iron simultaneously, as it increases toxicity and does not speed up the response.

Question 30: All of the following are true regarding Low Molecular Weight Heparin (LMWH) except?

A. It has higher and predictable bioavailability.
B. It inhibits both factor IIa and Xa. (Correct Answer)
C. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) monitoring is not required.
D. It has more favorable pharmacokinetics.

Explanation: **Explanation:** The correct answer is **B**, as it is a technically inaccurate statement regarding the primary mechanism of Low Molecular Weight Heparin (LMWH). **1. Why Option B is the correct answer (The "Except"):** While Unfractionated Heparin (UFH) inhibits both Factor Xa and Factor IIa (Thrombin) in a **1:1 ratio**, LMWH has a much higher affinity for **Factor Xa**. Due to its shorter polysaccharide chain length, LMWH lacks the necessary length to bridge Antithrombin III to Thrombin. Consequently, LMWH inhibits Factor Xa and IIa in a ratio ranging from **2:1 to 4:1**. It does not inhibit both equally. **2. Why the other options are incorrect (True statements):** * **Option A:** LMWH has higher (>90%) and more predictable bioavailability compared to UFH because it binds less to plasma proteins and endothelial cells. * **Option C:** Because of its predictable dose-response relationship, routine monitoring of PT or aPTT is **not required**. If monitoring is necessary (e.g., in renal failure or pregnancy), **Anti-Factor Xa levels** are measured. * **Option D:** LMWH has a longer half-life (4–6 hours) compared to UFH (1–2 hours), allowing for convenient once or twice-daily subcutaneous dosing. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** LMWH (e.g., Enoxaparin) is the preferred anticoagulant in **pregnancy** as it does not cross the placenta. * **Renal Clearance:** LMWH is primarily excreted by the kidneys; it is contraindicated or requires dose adjustment in **Chronic Kidney Disease (CKD)**. UFH is preferred in ESRD. * **Antidote:** Protamine sulfate completely neutralizes UFH but only **partially neutralizes** LMWH. * **HIT:** The risk of Heparin-Induced Thrombocytopenia (HIT) is significantly lower with LMWH than with UFH.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free